These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30135448)

  • 1. Genomic patterns of progression in smoldering multiple myeloma.
    Bolli N; Maura F; Minvielle S; Gloznik D; Szalat R; Fullam A; Martincorena I; Dawson KJ; Samur MK; Zamora J; Tarpey P; Davies H; Fulciniti M; Shammas MA; Tai YT; Magrangeas F; Moreau P; Corradini P; Anderson K; Alexandrov L; Wedge DC; Avet-Loiseau H; Campbell P; Munshi N
    Nat Commun; 2018 Aug; 9(1):3363. PubMed ID: 30135448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.
    Oben B; Froyen G; Maclachlan KH; Leongamornlert D; Abascal F; Zheng-Lin B; Yellapantula V; Derkach A; Geerdens E; Diamond BT; Arijs I; Maes B; Vanhees K; Hultcrantz M; Manasanch EE; Kazandjian D; Lesokhin A; Dogan A; Zhang Y; Mikulasova A; Walker B; Morgan G; Campbell PJ; Landgren O; Rummens JL; Bolli N; Maura F
    Nat Commun; 2021 Mar; 12(1):1861. PubMed ID: 33767199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.
    Bustoros M; Sklavenitis-Pistofidis R; Park J; Redd R; Zhitomirsky B; Dunford AJ; Salem K; Tai YT; Anand S; Mouhieddine TH; Chavda SJ; Boehner C; Elagina L; Neuse CJ; Cha J; Rahmat M; Taylor-Weiner A; Van Allen E; Kumar S; Kastritis E; Leshchiner I; Morgan EA; Laubach J; Casneuf T; Richardson P; Munshi NC; Anderson KC; Trippa L; Aguet F; Stewart C; Dimopoulos MA; Yong K; Bergsagel PL; Manier S; Getz G; Ghobrial IM
    J Clin Oncol; 2020 Jul; 38(21):2380-2389. PubMed ID: 32442065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.
    Kazandjian D; Diamond B; Papadimitriou M; Hill E; Sklavenitis-Pistofidis R; Ziccheddu B; Blaney P; Chojnacka M; Durante M; Maclachlan K; Young R; Usmani S; Davies F; Getz G; Ghobrial I; Korde N; Morgan G; Maura F; Landgren O
    Clin Cancer Res; 2024 Oct; 30(19):4482-4490. PubMed ID: 38652812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
    Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
    Front Immunol; 2021; 12():792609. PubMed ID: 34880879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
    Boyle EM; Deshpande S; Tytarenko R; Ashby C; Wang Y; Bauer MA; Johnson SK; Wardell CP; Thanendrarajan S; Zangari M; Facon T; Dumontet C; Barlogie B; Arbini A; Rustad EH; Maura F; Landgren O; Zhan F; van Rhee F; Schinke C; Davies FE; Morgan GJ; Walker BA
    Nat Commun; 2021 Jan; 12(1):293. PubMed ID: 33436579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma.
    Kumar S; Rajkumar SV; Jevremovic D; Kyle RA; Shifrin Y; Nguyen M; Husain Z; Alikhah A; Jafari A; Mai S; Anderson K; Louis S
    Am J Hematol; 2024 Aug; 99(8):1532-1539. PubMed ID: 38747543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
    Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Wang Y; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Dhodapkar MV; Davies FE; Morgan GJ; van Rhee F; Walker BA
    Leukemia; 2022 Feb; 36(2):591-595. PubMed ID: 34365473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.
    Ledergor G; Weiner A; Zada M; Wang SY; Cohen YC; Gatt ME; Snir N; Magen H; Koren-Michowitz M; Herzog-Tzarfati K; Keren-Shaul H; Bornstein C; Rotkopf R; Yofe I; David E; Yellapantula V; Kay S; Salai M; Ben Yehuda D; Nagler A; Shvidel L; Orr-Urtreger A; Halpern KB; Itzkovitz S; Landgren O; San-Miguel J; Paiva B; Keats JJ; Papaemmanuil E; Avivi I; Barbash GI; Tanay A; Amit I
    Nat Med; 2018 Dec; 24(12):1867-1876. PubMed ID: 30523328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Difficulty in Defining the True High-Risk Smoldering Myeloma.
    Weinhold N; Rasche L
    Clin Cancer Res; 2024 Oct; 30(19):4263-4265. PubMed ID: 39047171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.
    Maura F; Bolli N; Rustad EH; Hultcrantz M; Munshi N; Landgren O
    JAMA Oncol; 2020 Mar; 6(3):425-432. PubMed ID: 31830214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic analysis of high-risk smoldering multiple myeloma.
    López-Corral L; Mateos MV; Corchete LA; Sarasquete ME; de la Rubia J; de Arriba F; Lahuerta JJ; García-Sanz R; San Miguel JF; Gutiérrez NC
    Haematologica; 2012 Sep; 97(9):1439-43. PubMed ID: 22331267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
    Visram A; Cook J; Warsame R
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):673-681. PubMed ID: 34889380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smoldering multiple myeloma - Past, present, and future.
    Mann H; Katiyar V; Varga C; Comenzo RL
    Blood Rev; 2022 Mar; 52():100869. PubMed ID: 34312016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
    Mussetti A; Pellegrinelli A; Cieri N; Garzone G; Dominoni F; Cabras A; Montefusco V
    Ann Hematol; 2019 Jul; 98(7):1713-1720. PubMed ID: 31053880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.
    Bustoros M; Anand S; Sklavenitis-Pistofidis R; Redd R; Boyle EM; Zhitomirsky B; Dunford AJ; Tai YT; Chavda SJ; Boehner C; Neuse CJ; Rahmat M; Dutta A; Casneuf T; Verona R; Kastritis E; Trippa L; Stewart C; Walker BA; Davies FE; Dimopoulos MA; Bergsagel PL; Yong K; Morgan GJ; Aguet F; Getz G; Ghobrial IM
    Nat Commun; 2022 Jun; 13(1):3449. PubMed ID: 35705541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma.
    Francis ER; Chen F; Kidacki M; Miller R; Alkhasoneh M; Talamo G; Straub M; Klinefelter K; Kodali N; Zhu Y
    Clin Chim Acta; 2018 Dec; 487():306-308. PubMed ID: 30315756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
    Medina-Herrera A; Vazquez I; Cuenca I; Rosa-Rosa JM; Ariceta B; Jimenez C; Fernandez-Mercado M; Larrayoz MJ; Gutierrez NC; Fernandez-Guijarro M; Gonzalez-Calle V; Rodriguez-Otero P; Oriol A; Rosiñol L; Alegre A; Escalante F; De La Rubia J; Teruel AI; De Arriba F; Hernandez MT; Lopez-Jimenez J; Ocio EM; Puig N; Paiva B; Lahuerta JJ; Bladé J; San Miguel JF; Mateos MV; Martinez-Lopez J; Calasanz MJ; Garcia-Sanz R;
    Blood Cancer J; 2024 Apr; 14(1):74. PubMed ID: 38684670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.
    Chojnacka M; Diamond B; Landgren O; Maura F
    Semin Oncol; 2022 Feb; 49(1):11-18. PubMed ID: 35168813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoldering multiple myeloma: taking the narrow over the wide path?
    Avet-Loiseau H; Bahlis NJ
    Blood; 2024 May; 143(20):2025-2028. PubMed ID: 38427775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.